Darunavir (Prezista®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000363
English
Authors' recommendations:
Darunavir (Prezista®) co-administered with low dose ritonavir, in combination with other antiretroviral medicinal products, is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral treatment (ART)-experienced children and adolescents from the age of 6 years and at least 20 kg body weight.
Darunavir (Prezista®) should be prescribed in accordance with Paediatric European Network for Treatment of Aids (PENTA) guidelines.
Darunavir (Prezista®) is not suitable for shared care within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=170531&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Sulfonamides
- HIV Protease Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.